← ANALYST RATINGS · TIPRANKS
Scribe Therapeutics Inc. (SCTX): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $51.75, the highest $60.00, the lowest $37.00. The average is +157.7% from the last price of $20.08.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $60.00 | Buy | +198.8% | Reiterated | 03.09.26on TipRanks 06:15 | −1.3%next day −6.6% · 5 days −2.3% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $60.00 | Buy | +198.8% | Reiterated | 31.08.26on TipRanks Sep 8 06:20 | +7.7%next day −4.4% · 5 days +2.8% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $50.00 | Buy | +149.0% | Initiated | 18.08.26on TipRanks Aug 19 05:36 | +28.6%next day +14.3% · 5 days +15.3% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $37.00 | Buy | +84.3% | Initiated | 18.08.26on TipRanks 06:15 | +28.6%next day +14.3% · 5 days +15.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Scribe Therapeutics Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $51.75 at a price of $18.41 (+181.2%); now: $51.75 at $20.08 (+157.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 4 | 5 | 5 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Scribe Therapeutics Inc.
- CEO: Benjamin L. Oakes
- Employees: 89
- 1150 MARINA VILLAGE PARKWAY, Alameda, CA, 94501, US
- www.scribetx.com
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Data from the stock’s TipRanks forecast page, read 115 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗